ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2972

Cardiopulmonary Exercise Testing in Patients with Systemic Sclerosis: Unexplored Mechanisms of Dyspnea

Sara R. Schoenfeld1, George Alba2, Josanna Rodriguez-Lopez3, Richard N. Channick3, Flavia V. Castelino4 and Marcy B. Bolster4, 1Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Department of Pulmonary and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Pulmonary and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Dyspnea and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with systemic sclerosis (SSc) experience dyspnea for multiple reasons. Cardiopulmonary exercise testing (CPET), an important tool in the evaluation of undifferentiated dyspnea, provides integrated metabolic and hemodynamic measures during exercise. Few studies have utilized CPET in SSc.1 In this study we evaluated exercise limitations in SSc patients as determined by CPET combined with invasive hemodynamic measurements (level 3 CPET). 

Methods:

This was a single center, retrospective review of all SSc patients who underwent level 3 CPET between February 2006 and February 2015. Level 3 CPET consists of graded exercise on a cycle ergometer with metabolic cart and simultaneous measurement of pulmonary and systemic arterial hemodynamics. Primary reasons for exercise limitation include left ventricular diastolic dysfunction (LVDD), a peripheral limit (impairment in the ability of the muscles to extract and use oxygen), a pulmonary vascular limit (PVL, i.e. PAH) or a pulmonary mechanical limit. Demographic and clinical information was extracted from medical records.

Results:

Eleven patients were included in this analysis. Nine of the eleven patients met the 2013 ACR SSc classification criteria. Two had missing information that precluded the definitive classification as SSc, but fell within the spectrum of SSc disease. Baseline characteristics are shown in Table 1. 91% of patients were female and the mean age was 61 years. Seven of eleven (64%) patients had a peripheral extraction limitation; the remaining four had LVDD or PVL (Table 2). Three of the seven patients with a peripheral limit to exercise were anemic, defined by hemoglobin <12 g/dL, the lower limit of normal in our laboratory.

Conclusion:

Our findings provide novel insight into less explored etiologies of dyspnea and exercise limitation in SSc patients. Only one prior study reported findings similar to ours, but that study did not employ invasive CPET.2 Of note, only three of the seven patients with a peripheral limit in our study were anemic, suggesting alternative mechanisms for impaired peripheral oxygen extraction. The systemic vasculopathy characteristic of SSc is likely present in muscle and may contribute to impaired oxygen utilization. Our findings call for larger studies to address the possible mechanisms of peripheral limitation in SSc patients, and even suggest a potential therapeutic role for agents with vascular targets that may improve peripheral extraction, resulting in improved dyspnea and exercise tolerance in SSc patients.

References

1.      J. Rheum. 2010. 37:1871.

2.      Am J Med. 1993. 95:413.

 

 

Table 1 FINAL.png

Table 2 FINAL.png


Disclosure: S. R. Schoenfeld, None; G. Alba, None; J. Rodriguez-Lopez, Actelion Pharmaceuticals US, 2,Gilead, 5; R. N. Channick, Actelion Pharmaceuticals US, 2,Actelion Pharmaceuticals US, 5,Bayer, 2,Bayer, 5; F. V. Castelino, None; M. B. Bolster, Johnson and Johnson, 1,Eli Lilly and Company, 2,American College of Rheumatology, 6,Rheumatology Research Foundation, 6.

To cite this abstract in AMA style:

Schoenfeld SR, Alba G, Rodriguez-Lopez J, Channick RN, Castelino FV, Bolster MB. Cardiopulmonary Exercise Testing in Patients with Systemic Sclerosis: Unexplored Mechanisms of Dyspnea [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cardiopulmonary-exercise-testing-in-patients-with-systemic-sclerosis-unexplored-mechanisms-of-dyspnea/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiopulmonary-exercise-testing-in-patients-with-systemic-sclerosis-unexplored-mechanisms-of-dyspnea/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology